


CP-673451

Cat. No.:	HY-12050		
CAS No.:	343787-29-1		
Molecular Formula:	C ₂₄ H ₂₇ N ₅ O ₂		
Molecular Weight:	417.5		
Target:	PDGFR		
Pathway:	Protein Tyrosine Kinase/RTK		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 100 mg/mL (239.52 mM)
 * "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	2.3952 mL	11.9760 mL	23.9521 mL
	5 mM	0.4790 mL	2.3952 mL	4.7904 mL
	10 mM	0.2395 mL	1.1976 mL	2.3952 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
 Solubility: ≥ 2.75 mg/mL (6.59 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
 Solubility: ≥ 2.75 mg/mL (6.59 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

CP-673451 is a potent and selective inhibitor of PDGFR with IC₅₀s of 10 and 1 nM for PDGFRα and PDGFRβ, respectively.

IC₅₀ & Target

PDGFRα	PDGFRβ
10 nM (IC ₅₀)	1 nM (IC ₅₀)

In Vitro

CP-673451 efficiently suppresses the PDGFR downstream signaling pathway. It inhibits phosphorylation of Akt, GSK-3β, p70S6, and S6 in A549 cells in a concentration-dependent manner. CP-673451 (0.0625-4 μM) significantly reduces the viability of NSCLC cell lines A549 and H1299 in a time- and concentration-dependent manner, with IC₅₀s of 0.49 and 0.61 μM, respectively. CP-673451 (1, 4 μM) induces apoptosis in non-small-cell lung cancer cells. CP-673451 (25, 100, or 400 nM) is

effective at inhibiting migration and invasion of NSCLC cells by suppression of lamellipodia formation^[1]. CP-673451 and crenolanib show selective lethality toward cells with CA. U2OS cells treated with 1 to 4 μM CP-673451 or crenolanib show a ruffled cell surface as a sign for alterations of the cortical actin cytoskeleton. CP-673451 attenuates PDGF-BB-induced signaling, and significantly enhances the phosphorylation of PDGFR- β downstream effectors, Akt and MEK^[2]. CP-673,451 (0.5 μM) regulates cell proliferation through mechanisms involving reduced phosphorylation of GSK-3 α and GSK-3 β . CP-673,451 impairs rhabdosphere-forming capacity in both RD and RUCH2 cultures^[3]. CP-673,451 inhibits PDGFR- β in PAE- β cells with an IC_{50} value of 6.4 nM. Besides, CP-673,451 incubation in H526 and PAE- β cells results in an IC_{50} value of 1.1 μM against c-kit^[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

CP-673451 (20 mg/kg) leads to a medium suppression of tumor growth, while high-dose CP-673451 (40 mg/kg) strongly inhibits tumor growth in mice without significant weight loss^[1]. CP-673,451 (10, 33, and 100 mg/kg, p.o., b.i.d) inhibits the growth of Colo205 tumor in a dose-dependent manner, and similar tumor growth inhibition experiments completed on LS174T, H460, and U87MG xenografts, with no signs of morbidity or weight loss^[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Cell Assay ^[3]

Cell proliferation/viability is analyzed using the CyQuant proliferation assay. Pre-starved cells are treated every 24 hours with vehicle (dimethyl sulfoxide) or 0.5 μM CP-673,451 diluted in serum-reduced medium (1.5% FBS) for 96 hours. The amount of nucleic acid present in lysed cells is normalized to the amount when treatment is initiated. Cell proliferation/viability in response to 300 ng/mL PDGF-CC is likewise analyzed, but cells are then kept in serum-free medium and treated twice during a 48-hour period.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration ^[1]

A subcutaneous A549 xenograft model in nude mice is used to evaluate the anticancer activity of CP-673451. Briefly, A549 cells are injected into the axillary regions of mice (2×10^6 cells/mouse). When the tumor volumes reach 70 mm^3 , the mice are randomly assigned to a control group and two CP-673451 groups ($n=6$ per group): low-dose (20 mg/kg) and high dose (40 mg/kg) groups (vehicle 10% 1-methyl-2-pyrrolidinone and 90% polyethylene glycol 300). These animals are administered intraperitoneally with CP-673451 (20 or 40 mg/kg/day) or with vehicle. During the treatment period, the implanted tumors are measured by caliper once a day in a blind fashion. The animal body weights are also measured at the same time. The tumor volume is calculated. After treatment, the mice are killed, and the tumors are harvested and analyzed.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Clin Cancer Res. 2019 Feb 1;25(3):1070-1086.
- Cell Rep. 2023 Jul 16;42(7):112794
- J Invest Dermatol. 2019 Jul;139(7):1574-1582.
- Glia. 2020 Feb;68(2):345-355.
- Cancers (Basel). 2023 Apr 26, 15(9), 2498.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Xi Y, et al. CP-673451, a platelet-derived growth-factor receptor inhibitor, suppresses lung cancer cell proliferation and migration. Onco Targets Ther. 2014 Jul 3;7:1215-

21.

[2]. Konotop G, et al. Pharmacological Inhibition of Centrosome Clustering by Slingshot-Mediated Cofilin Activation and Actin Cortex Destabilization. *Cancer Res.* 2016 Nov 15;76(22):6690-6700

[3]. Ehnman M, et al. Distinct effects of ligand-induced PDGFR α and PDGFR β signaling in the human rhabdomyosarcoma tumor cell and stroma cell compartments. *Cancer Res.* 2013, 73(7), 2139-2149.

[4]. Roberts WG, et al. Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451. *Cancer Res.* 2005, 65(3), 957-966.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA